{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:09:57Z","timestamp":1786990197118,"version":"build-2736575974"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.hoc.2016.11.001","type":"journal-article","created":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T16:51:57Z","timestamp":1490287917000},"page":"209-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Management of Anaplastic Large Cell Lymphoma"],"prefix":"10.1016","volume":"31","author":[{"given":"Dai","family":"Chihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Fanale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.hoc.2016.11.001_bib1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2016.11.001_bib2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/bjh.12659","article-title":"Differences in incidence and trends of haematological malignancies in Japan and the United States","volume":"164","author":"Chihara","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.001_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2016.11.001_bib4","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.2015.63.5540","article-title":"Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States","volume":"34","author":"Adams","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.hoc.2016.11.001_bib5","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.hoc.2016.11.001_bib6","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1200\/JCO.2012.42.5611","article-title":"Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study","volume":"31","author":"Piccaluga","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2016.11.001_bib7","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1182\/blood-2012-01-405555","article-title":"Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma","volume":"120","author":"Agnelli","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.001_bib8","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JCO.2013.52.7911","article-title":"Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients","volume":"32","author":"Miranda","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"32","key":"10.1016\/j.hoc.2016.11.001_bib9","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2012.42.2345","article-title":"Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials","volume":"30","author":"Sibon","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2016.11.001_bib10","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the international peripheral T-Cell lymphoma project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"issue":"40","key":"10.1016\/j.hoc.2016.11.001_bib11","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.1038\/sj.onc.1204594","article-title":"Translocations involving anaplastic lymphoma kinase (ALK)","volume":"20","author":"Duyster","year":"2001","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.hoc.2016.11.001_bib12","first-page":"3509","article-title":"Lymphomas expressing ALK fusion protein(s) other than NPM-ALK","volume":"94","author":"Falini","year":"1999","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2016.11.001_bib13","article-title":"The survival outcome of the patients with relapsed\/refractory anaplastic large-cell lymphoma","volume":"126","author":"Chihara","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.001_bib14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/PAS.0000000000000500","article-title":"Morphologic features of ALK-negative anaplastic large cell lymphomas with DUSP22 rearrangements","volume":"40","author":"King","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"10.1016\/j.hoc.2016.11.001_bib15","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.001_bib16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2014-12-614503","article-title":"Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts","volume":"127","author":"Scarfo","year":"2016","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2016.11.001_bib17","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2016.11.001_bib18","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1200\/JCO.2008.20.9759","article-title":"Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms","volume":"28","author":"Piva","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2016.11.001_bib19","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood-2009-06-227579","article-title":"Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma","volume":"115","author":"Iqbal","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2016.11.001_bib20","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/blood-2006-06-028969","article-title":"Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes","volume":"109","author":"Lamant","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2016.11.001_bib21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ccell.2015.03.006","article-title":"Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma","volume":"27","author":"Crescenzo","year":"2015","journal-title":"Cancer cell"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.001_bib22","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1200\/JCO.2015.63.3412","article-title":"Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma","volume":"34","author":"Clemens","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.001_bib23","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2016.11.001_bib24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bjh.13628","article-title":"Phase II study of HCVIDD\/MA in patients with newly diagnosed peripheral T-cell lymphoma","volume":"171","author":"Chihara","year":"2015","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.hoc.2016.11.001_bib25","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.hoc.2016.11.001_bib26","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2016.11.001_bib27","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1080\/1042819021000006277","article-title":"Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas","volume":"43","author":"Lee","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"10.1016\/j.hoc.2016.11.001_bib28","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","article-title":"Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma","volume":"369","author":"Stiff","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.hoc.2016.11.001_bib29","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.001_bib30","doi-asserted-by":"crossref","first-page":"623924","DOI":"10.5402\/2011\/623924","article-title":"A\u00a0systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma","volume":"2011","author":"Abouyabis","year":"2011","journal-title":"ISRN Hematol"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.001_bib31","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/annonc\/mdu515","article-title":"Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center","volume":"26","author":"Loirat","year":"2015","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.hoc.2016.11.001_bib32","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2016.11.001_bib33","doi-asserted-by":"crossref","first-page":"10540","DOI":"10.1074\/jbc.M510026200","article-title":"Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates","volume":"281","author":"Sutherland","year":"2006","journal-title":"J\u00a0Biol Chem"},{"issue":"18","key":"10.1016\/j.hoc.2016.11.001_bib34","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2016.11.001_bib35","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3095.3095","article-title":"Four-year survival data from an ongoing pivotal phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"124","author":"Pro","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.001_bib36","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.1809.1809","article-title":"Three-year survival results from an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"122","author":"Pro","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.001_bib37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"7","author":"Bartlett","year":"2014","journal-title":"J\u00a0Hematol Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2016.11.001_bib38","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3324\/haematol.2012.069393","article-title":"Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center","volume":"98","author":"Gibb","year":"2013","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.hoc.2016.11.001_bib39","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2016.11.001_bib40","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.001_bib41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J\u00a0Hematol Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2016.11.001_bib42","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1182\/blood.V124.21.1748.1748","article-title":"Phase I Study of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"124","author":"Chihara","year":"2014","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2016.11.001_bib43","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral t-cell lymphoma: results of the pivotal Phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2016.11.001_bib44","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/annonc\/mdg702","article-title":"Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma","volume":"14","author":"Zelenetz","year":"2003","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.001_bib45","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3816\/CLM.2004.n.009","article-title":"Pilot study of fixed-infusion rate gemcitabine with cisplatin and dexamethasone in patients with relapsed or refractory lymphoma","volume":"5","author":"Emmanouilides","year":"2004","journal-title":"Clin Lymphoma"},{"issue":"6","key":"10.1016\/j.hoc.2016.11.001_bib46","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.3109\/10428194.2012.739286","article-title":"Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma","volume":"54","author":"Yao","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.hoc.2016.11.001_bib47","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.bmt.1705712","article-title":"Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen","volume":"40","author":"Smith","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.hoc.2016.11.001_bib48","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-007-0254-1","article-title":"High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival","volume":"86","author":"Kim","year":"2007","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.hoc.2016.11.001_bib49","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/leu.2012.321","article-title":"Comparison of outcomes between autologous and allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphomas with central review of pathology","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.hoc.2016.11.001_bib50","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/annonc\/mdq698","article-title":"A\u00a0large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides\/Sezary syndrome","volume":"22","author":"Jacobsen","year":"2011","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.hoc.2016.11.001_bib51","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.001_bib52","first-page":"124","article-title":"Reduced-intensity conditioning of allogeneic transplantation for nodal peripheral T-cell lymphomas","author":"Aoki","year":"2014","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"25","key":"10.1016\/j.hoc.2016.11.001_bib53","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"28","key":"10.1016\/j.hoc.2016.11.001_bib54","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study","volume":"32","author":"Fanale","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2016.11.001_bib55","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","article-title":"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study","volume":"14","author":"Mosse","year":"2013","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.001_bib56","doi-asserted-by":"crossref","first-page":"djt378","DOI":"10.1093\/jnci\/djt378","article-title":"Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients","volume":"106","author":"Gambacorti Passerini","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"23","key":"10.1016\/j.hoc.2016.11.001_bib57","volume":"126","author":"Sawas","year":"2015","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2016.11.001_bib58","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.3987.3987","article-title":"High response rate of romidepsin in combination with ICE (Ifosfamide, Carboplatin and Etoposide) in patients with relapsed or refractory peripheral T-cell lymphoma: updates of phase I trial","volume":"126","author":"Chihara","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2016.11.001_bib59","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T\u00a0cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2016.11.001_bib60","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N\u00a0Engl J Med"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858816301691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858816301691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:04:23Z","timestamp":1760184263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858816301691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0889858816301691"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2016.11.001","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Anaplastic Large Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2016.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}